<DOC>
	<DOCNO>NCT01721564</DOCNO>
	<brief_summary>6 month therapy Bosentan , endothelin antagonist , lead improvement pulmonary microvascular endothelial function .</brief_summary>
	<brief_title>Bosentan Pulmonary Endothelial Function</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<mesh_term>Bosentan</mesh_term>
	<criteria>Pulmonary arterial hypertension ; idiopathic connective tissue disease associate Confirmed invasive haemodynamic : Mean pulmonary arterial pressure great equal 25 millimeter mercury Pulmonary capillary wedge pressure le 15 millimeter mercury No prior pulmonary hypertension specific therapy Ability provide inform consent Contraindications medication use test endothelial function ; acetylcholine , sodium nitroprusside , NGMonomethylLArginine , Larginine Advanced renal disease Previous allergic reaction contrast agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>